vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and VICOR CORP (VICR). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $113.0M, roughly 1.2× VICOR CORP). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 18.3%, a 17.2% gap on every dollar of revenue. On growth, VICOR CORP posted the faster year-over-year revenue change (20.2% vs 18.4%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 14.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
ADMA vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $113.0M |
| Net Profit | $49.4M | $20.7M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 59.7% |
| Net Margin | 35.5% | 18.3% |
| Revenue YoY | 18.4% | 20.2% |
| Net Profit YoY | -55.9% | 713.9% |
| EPS (diluted) | $0.20 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $139.2M | $107.3M | ||
| Q3 25 | $134.2M | $110.4M | ||
| Q2 25 | $122.0M | $96.0M | ||
| Q1 25 | $114.8M | $94.0M | ||
| Q4 24 | $117.5M | $96.2M | ||
| Q3 24 | $119.8M | $93.2M | ||
| Q2 24 | $107.2M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | $49.4M | $46.5M | ||
| Q3 25 | $36.4M | $28.3M | ||
| Q2 25 | $34.2M | $41.2M | ||
| Q1 25 | $26.9M | $2.5M | ||
| Q4 24 | $111.9M | $10.2M | ||
| Q3 24 | $35.9M | $11.6M | ||
| Q2 24 | $32.1M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | 55.4% | ||
| Q3 25 | 56.3% | 57.5% | ||
| Q2 25 | 55.1% | 95.9% | ||
| Q1 25 | 53.2% | 47.2% | ||
| Q4 24 | 53.9% | 52.4% | ||
| Q3 24 | 49.8% | 49.1% | ||
| Q2 24 | 53.6% | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | 45.1% | 14.6% | ||
| Q3 25 | 38.0% | 18.9% | ||
| Q2 25 | 35.1% | 47.3% | ||
| Q1 25 | 30.4% | -0.2% | ||
| Q4 24 | 32.6% | 9.6% | ||
| Q3 24 | 33.1% | 5.8% | ||
| Q2 24 | 36.6% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | 35.5% | 43.4% | ||
| Q3 25 | 27.1% | 25.6% | ||
| Q2 25 | 28.1% | 42.9% | ||
| Q1 25 | 23.4% | 2.7% | ||
| Q4 24 | 95.2% | 10.7% | ||
| Q3 24 | 30.0% | 12.4% | ||
| Q2 24 | 29.9% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $0.20 | $1.01 | ||
| Q3 25 | $0.15 | $0.63 | ||
| Q2 25 | $0.14 | $0.91 | ||
| Q1 25 | $0.11 | $0.06 | ||
| Q4 24 | $0.45 | $0.24 | ||
| Q3 24 | $0.15 | $0.26 | ||
| Q2 24 | $0.13 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $404.2M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $754.1M |
| Total Assets | $624.2M | $804.9M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $87.6M | $402.8M | ||
| Q3 25 | $61.4M | $362.4M | ||
| Q2 25 | $90.3M | $338.5M | ||
| Q1 25 | $71.6M | $296.1M | ||
| Q4 24 | $103.1M | $277.3M | ||
| Q3 24 | $86.7M | $267.6M | ||
| Q2 24 | $88.2M | $251.9M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $477.3M | $711.6M | ||
| Q3 25 | $431.2M | $630.1M | ||
| Q2 25 | $398.3M | $608.6M | ||
| Q1 25 | $373.4M | $580.3M | ||
| Q4 24 | $349.0M | $570.1M | ||
| Q3 24 | $231.9M | $554.6M | ||
| Q2 24 | $188.3M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $624.2M | $785.8M | ||
| Q3 25 | $568.7M | $710.2M | ||
| Q2 25 | $558.4M | $693.5M | ||
| Q1 25 | $510.6M | $665.0M | ||
| Q4 24 | $488.7M | $641.1M | ||
| Q3 24 | $390.6M | $632.8M | ||
| Q2 24 | $376.4M | $613.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $15.7M | ||
| Q3 25 | $13.3M | $38.5M | ||
| Q2 25 | $21.1M | $65.2M | ||
| Q1 25 | $-19.7M | $20.1M | ||
| Q4 24 | $50.2M | $10.1M | ||
| Q3 24 | $25.0M | $22.6M | ||
| Q2 24 | $45.6M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $10.2M | ||
| Q3 25 | $-1.1M | $34.5M | ||
| Q2 25 | $18.7M | $59.0M | ||
| Q1 25 | $-24.4M | $15.6M | ||
| Q4 24 | $47.5M | $8.4M | ||
| Q3 24 | $24.0M | $14.1M | ||
| Q2 24 | $43.6M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 9.5% | ||
| Q3 25 | -0.8% | 31.2% | ||
| Q2 25 | 15.3% | 61.5% | ||
| Q1 25 | -21.2% | 16.6% | ||
| Q4 24 | 40.4% | 8.7% | ||
| Q3 24 | 20.0% | 15.2% | ||
| Q2 24 | 40.7% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 5.2% | ||
| Q3 25 | 10.7% | 3.6% | ||
| Q2 25 | 2.0% | 6.5% | ||
| Q1 25 | 4.1% | 4.8% | ||
| Q4 24 | 2.3% | 1.8% | ||
| Q3 24 | 0.9% | 9.1% | ||
| Q2 24 | 1.9% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 0.34× | ||
| Q3 25 | 0.36× | 1.36× | ||
| Q2 25 | 0.62× | 1.58× | ||
| Q1 25 | -0.73× | 7.93× | ||
| Q4 24 | 0.45× | 0.99× | ||
| Q3 24 | 0.70× | 1.95× | ||
| Q2 24 | 1.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
